Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...

Incyte (NASDAQ:INCY – Get Free Report) had its target price dropped by equities research analysts at Morgan Stanley from $69.00 to $65.00 in a research report issued to clients and investors on ...

Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company specializing in oncology and dermatology, finds itself at a critical juncture as it navigates the impending loss of patent protection ...

Incyte (NASDAQ:INCY – Get Free Report) was downgraded by William Blair from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, Marketbeat.com reports.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes.

Corient Private Wealth LLC lifted its position in Incyte Co. (NASDAQ:INCY – Free Report) by 3.5% during the fourth quarter, according to its most recent 13F filing with the SEC.The institutional ...

Thrivent Financial for Lutherans boosted its holdings in Incyte Co. (NASDAQ:INCY – Free Report) by 314.3% during the fourth quarter, Holdings Channel.com reports.The firm owned 30,377 shares of ...

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's ...